GOLGA2

Across TCGA pan-cancer cohorts, GOLGA2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GOLGA2 data layer compared with 23 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher GOLGA2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GOLGA2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

UCEC, HNSC, and LUAD are the cancer types where GOLGA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	II,III,IV	1.000	0.417	.002	34	view →
HNSC	DFS	Median	All	0.851	0.353	.028	8	view →
LUAD	OS	Median	III,IV	0.782	0.449	.028	7	view →
PDAC	OS	Median	IV	0.491	0.836	.024	3	view →
CCRCC	DFS	Median	All	1.000	0.733	.020	2	view →
GBM	OS	Quartile	All	0.619	0.864	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GOLGA2–UCEC (DFS)

Open the UCEC breakdown →